Search results
Oct 21, 2022 · The company is developing neffy® (previously referred to as ARS-1), an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions including food, medications and insect bites that could lead to life-threatening anaphylaxis.
May 11, 2023 · Neffy is designed to deliver a 2 milligram dose of epinephrine, which can reverse the symptoms of a life-threatening allergic reaction. The company is seeking the FDA's approval...
Sep 20, 2023 · The nasal-spray Neffy was rejected by the FDA. The epinephrine nasal spray would've been the first needle-free alternative to EpiPens, but the FDA said additional research was needed.
Jan 24, 2024 · The makers of the epinephrine nasal spray called neffy are pushing forward in the effort to win approval from the Food and Drug Administration. Allergic Living checked in with Richard Lowenthal, CEO and president of ARS Pharma, to find out where things stand.
Sep 21, 2023 · The Food and Drug Administration on Tuesday did not approve Neffy, an epinephrine nasal spray from drugmaker ARS Pharmaceuticals, keeping the first needle-free option for Americans to treat...
May 11, 2023 · If the nasal spray – called neffy by ARS Pharmaceuticals – is approved, it would become the first needle-free epinephrine device.
neffy® (epinephrine) is an intranasal epinephrine formulation in development for the treatment of allergic reactions (Type 1), including anaphylaxis, for adults and children ≥30 kg.
Mar 7, 2024 · Neffy is an investigational nasal spray that contains epinephrine (nasal epi) which may be given to treat a severe allergic reaction, including anaphylaxis, in adults and children who weigh at least 30kg. It is needle-free and simple to administer.
Mecca Russell, known professionally as Neffy, is a singer-songwriter from Arlington, Virginia. In 2021, she won the NPR Tiny Desk Contest.
Sep 20, 2023 · If approved, Neffy would be the first needle-free nasal spray epinephrine treatment for people with severe allergic reactions. About 40 million people in the US experience extreme...
